Stefan Heinrich

Summary

Publications

  1. ncbi Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Department of General and Abdominal Surgery, University Hospital of Mainz, Langenbeck Strasse 1, 55118 Mainz, Germany
    BMC Cancer 11:346. 2011

Detail Information

Publications1

  1. ncbi Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Department of General and Abdominal Surgery, University Hospital of Mainz, Langenbeck Strasse 1, 55118 Mainz, Germany
    BMC Cancer 11:346. 2011
    ..Moreover, neoadjuvant chemotherapy improves the nutritional status of patients with pancreatic cancer. This multicenter phase III trial (NEOPAC) has been designed to explore the efficacy of neoadjuvant chemotherapy...